Combination therapy consisting of once-daily macitentan and tadalafil was associated with reductions in pulmonary vascular resistance in patients with pulmonary arterial hypertension. NEW ORLEANS – ...

FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced. The fixed ...

REPAIR study findings outline the benefits of macitentan for right ventricular functioning in pulmonary arterial hypertension. Results of the REPAIR (Right vEntricular remodeling in Pulmonary ArterIal ...

Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension. SAN ANTONIO — In patients with ...

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study. The combination is ...

Please provide your email address to receive an email when new articles are posted on . Treatment with a 10-mg dose of macitentan significantly decreased the risk for and prevalence of all-cause ...

Please provide your email address to receive an email when new articles are posted on . Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world ...

The study found no significant differences between the groups in terms of disease progression, morbidity or mortality, or all-cause death. Macitentan demonstrated superiority over other endothelin ...

Actelion Pharmaceuticals Ltd / Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension . Processed and transmitted by ...

ATLANTA — Macitentan significantly reduced morbidity and mortality in patients with pulmonary arterial hypertension (PAH), according to findings from the phase 3 SERAPHIN trial. Lewis Rubin, MD, from ...

In an oral presentation, Dr Nazzareno Galiè from the Institute of Cardiology, University of Bologna, Bologna, Italy presented data evaluating the association between 6MWD, a measure of exercise ...

Apotex appealed the trial decision, finding that Apo-Macitentan would infringe Canadian Patent No. 2,659,770 (770 Patent). Even though Apotex would only sell Apo-Macitentan by itself, the Federal ...